india-istock-182157035-ericsphotography-
ericsphotography / iStockphoto.com
28 January 2019Asia

Indian committee advocates compulsory licensing and price caps

Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.

More on this story

Asia
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.

More on this story

Asia
9 February 2016   India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.